Tesamorelin

Unlike synthetic growth hormone injections that supply external hormone, Tesamorelin stimulates your pituitary gland to release GH naturally. This preserves your body’s feedback loop, promotes a physiologic rhythm, and lowers the risk of excessive IGF-1 elevation or water retention.

Yes. Tesamorelin (Egrifta®) is FDA-approved for reducing visceral abdominal fat in HIV-associated lipodystrophy. Its use in longevity or aesthetic medicine is considered off-label—meaning supported by a scientific rationale but is outside the original approval.

Most patients notice improved sleep, focus, and morning energy within a few weeks. Visible changes—such as slimmer waist contours and improved muscle definition—typically appear after two to three months of consistent use and lifestyle adjustments.

Protocols are usually structured in 3- to 6-month cycles, followed by reassessment. Some patients transition to maintenance dosing or complementary peptide regimens once their goals—such as fat reduction, energy restoration, or metabolic balance—are achieved.

No—its effect is generally the opposite. Clinical trials have demonstrated a reduction in visceral fat while preserving lean mass. However, transient fluid retention or mild injection-site redness may occur early in treatment and typically resolve within a few days.

Absolutely. Because insulin can blunt GH release, evening meals lower in simple carbohydrates help optimize outcomes. Regular resistance training, restorative sleep, and stress-management practices also amplify Tesamorelin’s natural hormone-pulsing benefits.

Tesamorelin is generally well-tolerated. The most commonly reported effects include mild injection-site irritation, joint stiffness, tingling sensations, and temporary fluid retention. Rarely, glucose intolerance or carpal-tunnel-like symptoms can occur. Serious adverse events are uncommon when therapy is physician-monitored and labs are regularly reviewed.